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THE PROTECTIVE EFFECT OF FAT SPECIFIC PROTEIN 27 ON TUMOR 
NECROSIS FACTOR-ALPHA INDUCED LIPOLYSIS AND INSULIN 
RESISTANCE IN HUMAN ADIPOCYTES 
AMBER HYESUK LIM 
ABSTRACT 
 Adipose tissue is a key regulator of energy metabolism and glucose 
homeostasis by promoting triglyceride storage and breakdown in various 
physiological states. Obesity, however, alters adipose tissue metabolism, 
inducing chronic inflammation, followed by excessive lipolysis. This results in 
higher systemic free fatty acid (FFA) levels, leading to desensitization of insulin 
signaling and ultimately to insulin resistance. Although the link between obesity 
and progression of insulin resistance and type 2 diabetes mellitus (T2DM) 
remains unclear, tumor necrosis factor-α (TNF-α) has been proposed to be a key 
player in promoting obesity-related development of T2DM through chronic 
inflammation of adipose tissue. TNF-α has direct and indirect mechanisms by 
which it elicits insulin resistance in adipocytes. TNF-α attenuates insulin signaling 
by directly inhibiting insulin-stimulated tyrosine phosphorylation of the insulin 
receptor and insulin receptor substrate-1 (IRS-1). Indirectly, TNF-α activates 
signaling pathways to increase lipolysis and FFA release into circulation, leading 
to insulin resistance. Lipid droplet-associated fat specific protein 27 (FSP27) 
protects adipocytes from lipolysis by regulating the lipolytic capacity as well as 
transcription of adipose triglyceride lipase (ATGL). It has been observed that 
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TNF-α promotes lipolysis by reducing the expression of FSP27 in murine 
adipocytes. The effect of TNF-α on lipolysis human adipocytes has also been 
studied; yet its effect on promoting insulin resistance in human adipocytes still 
remains elusive. In the present study, we examined the effect of FSP27 on TNF-
α induced lipolysis and insulin resistance in human adipocytes. TNF-α enhanced 
lipolysis in cultured human adipocytes. In addition, TNF-α reduced the 
expression of endogenous FSP7 and the phosphorylation of AKT, inhibiting the 
activation of insulin signaling pathway in cultured human adipocytes. FSP27 
overexpression, however, attenuated TNF-α induced lipolysis and restored 
activation of insulin signaling through phosphorylation of AKT in cultured human 
adipocytes. Taken together, these data suggest that FSP27 has a protective 
effect against TNF-α induced lipolysis and insulin resistance through regulating 
lipolysis and insulin signaling in human adipocytes.  
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INTRODUCTION 
Obesity is a modern-day epidemic  
          The prevalence of obesity is a globally recognized problem as a result of 
urbanization with more availability of food, surplus of energy intake, and 
sedentary lifestyle. In the United States, two-thirds of the population is obese, 
defined as having a BMI of greater than 30 kg/m2, and with it comes pathological 
consequences comprised of various metabolic diseases, including cardiovascular 
disease, atherosclerosis, and in particular, type 2 diabetes mellitus (T2DM) [2]. 
Statistics reveal that T2DM is projected to double world-wide to 350 million cases 
by 2030. In the U.S., $132 billion yearly expenditure is devoted to prevention and 
treatment of T2DM [3, 4]. 
Obesity, Insulin resistance, and T2DM  
Although the mechanism is not fully understood, obesity is associated with 
insulin resistance, defined as the body's inability to respond to insulin properly, 
which plays a major role in the onset of T2DM [5]. Obesity-related insulin 
resistance that leads to the development of T2DM exhibits two common features. 
First, development of T2DM starts with a precondition where insulin-responsive 
peripheral tissues, such as the liver, skeletal muscle, and adipose tissue, fail to 
respond to insulin [1]. Further progression of insulin resistance ultimately gives 
rise to T2DM when the function of pancreatic beta cells is impaired and they fail 
to secrete the necessary levels of insulin to maintain normal glucose levels [6-8].  
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Metabolic consequences of insulin resistance 
 Because insulin plays a critical role in energy and metabolic homeostasis, 
development of insulin resistance in major insulin-responsive tissues brings 
detrimental consequences and leads to fundamental defects in function [9, 10]. 
Insulin resistance leads to hyperglycemia most notably, which result from various 
causes such as failure of insulin to suppress hepatic glucose production and to 
promote glucose uptake and metabolism by peripheral tissues. Hyperglycemia 
may also arise from dysfunctional pancreatic beta cells and their failure to 
respond to excess plasma glucose and to secrete insulin effectively. With 
progression of insulin resistance, pancreatic beta cells produce excess insulin in 
order to maintain normal plasma glucose concentration. However, beta cells 
ultimately fail to maintain adequate levels of insulin secretion and thus plasma 
glucose level increases and T2DM develops [9, 10]. 
 The development of insulin resistance is often attributed to the failure of 
insulin signaling because of excess free fatty acids (FFAs) in circulation as well. 
Increased plasma FFA impairs insulin signaling and promotes FFA oxidation in 
insulin-responsive tissues [11-13]. High plasma FFA provides substrate for 
hepatic TG synthesis (results in fatty liver), provides substrate for 
gluconeogenesis for hepatic glucose production, and leads to more VLDL 
secretion in the liver to reduce overall insulin sensitivity [14, 15]. Increased 
plasma FFA leads to the impairment of insulin signaling and decreased glucose 
uptake and glycogen synthesis, which all contribute to reduce insulin sensitivity in 
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the skeletal muscle [13]. High plasma FFA levels are toxic to pancreatic beta 
cells, accelerating dysfunction and apoptosis of the beta cells [16]. High plasma 
FFA levels affect adipose tissue by decreasing clearance of plasma TG rich 
lipoproteins by inhibiting LPL activity, reducing insulin sensitivity overall [15, 17].  
 Taken together, excess plasma FFA interferes with insulin signaling in 
major insulin-responsive tissues to contribute to the development of metabolic 
diseases which ultimately progresses into T2DM [18].  
Adipose tissue plays a critical role in energy metabolism  
Adipose tissue is a master regulator in maintaining whole-body glucose 
and energy homeostasis by regulating storage and breakdown of triglyceride [1]. 
Adipose tissue is also the gatekeeper for fatty acids in circulation where in 
postprandial state, secretion of insulin promotes glucose uptake, synthesis and 
accumulation of TG into lipid droplets in adipocytes while suppressing lipolysis 
and FFA release [1]. During fasting, adipocytes undergo lipolysis to break down 
TG stores to release FFA into circulation to serve as a major source of energy. 
On the other hand, adipocytes store excess nutrient into TG and then utilize TG 
stores to release FFA to the rest of the body in starvation to power glucose 
production to maintain whole-body glucose homeostasis [18].  
Obesity causes chronic inflammation in adipose tissue leading to insulin 
resistance 
In a normal, non-obese condition, adipose tissue regulates the release of 
a number of adipose tissue-derived factors, such as FFA, glycerol, hormones, 
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and adipokines in an optimal manner depending on physiological and metabolic 
needs [18]. But in obese conditions, FFA and other adipose tissue-associated 
factors are released uncontrollably into circulation [1]. In addition, nutrient excess 
in obesity leads to adipocyte enlargement, hypertrophy, and such progressive 
adipocyte enlargement leads to reduced blood supply to adipose tissue to result 
in hypoxia [19]. Hypoxic environment of adipose tissue elicits necrosis and 
release of macrophage chemoattractants, most notably MCP-1 [1]. Release of 
MCP-1 causes macrophage recruitment and infiltration into adipose tissue, 
causing local inflammation of the adipose tissue [20]. Such localized 
inflammation induces lipolysis, secreting more FFAs to propagate an overall 
systemic inflammation in a feed-forward process leading to a chronic 
inflammation (Figure 1d) [1, 20, 21]. MCP-1 also encourages the release of a 
number of pro-inflammatory cytokines, most notably tumor necrosis factor α 
(TNF-α), to elicit lipolysis and FFA release, contributing to the development of 
chronic inflammation (Figure 1) [1].  
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Figure 1: Obesity causes chronic inflammation in adipose tissue leading to 
a systemic insulin resistance [1]. (a) Small adipocytes store TG efficiently in 
lean state, which can be mobilized during starvation to peripheral tissues such as 
the skeletal muscle. (b) Small adipocytes become enlarged, hypertrophied, due 
to increased TG storage during excess caloric intake. (c) With further caloric 
intake, TG overloading continues; hypertrophy of adipocytes leads to hypoxia; 
macrophage chemoattractant secretion occurs, most notably MCP-1, recruiting 
additional macrophages to the site. (d) Macrophage recruitment and infiltration 
into adipose tissue results in more inflammation causing a pro-inflammatory state 
in obese, hypertrophied adipose tissue; infiltration of macrophages promotes the 
release of tumor necrosis factor-α (TNF-α), which results in a chronic 
inflammation and impaired adipocyte function; excessive lipolysis and ineffective 
TG storage disrupts insulin signaling in peripheral tissues, such as the skeletal 
muscle.  
 
TNF-α is a modulator of obesity-induced insulin resistance  
Tumor necrosis factor-α (TNF-α) is a multi-functional regulatory cytokine 
involved in inflammation, cell apoptosis and survival, cytotoxicity, production of 
other cytokines, and induction of insulin resistance [18]. TNF-α plays a critical 
role in insulin sensitivity both locally and systematically through various 
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mechanisms affecting adipose tissue metabolism [18]. A plethora of studies 
examined the role of TNF-α in insulin signaling and insulin resistance. TNF-α has 
been proposed to be a major factor stimulating lipolysis and triggering FFA 
release from the adipose tissue [18]. TNF-α inhibits LPL activity in 3T3-L1 
adipocytes to yield high plasma FFA and reduce insulin signaling [22, 23]. Long 
term exposure to TNF-α induces insulin resistance both in vivo and in vitro, 
whereas neutralization of TNF-α in Zucker rats increases insulin sensitivity [22-
24]. Absence of TNF-α or TNF-α receptors in knock-out mice improves insulin 
sensitivity in obese rodents [25, 26]. However, neutralizing TNF-α in obese T2DM 
patients failed to restore insulin sensitivity [27]. Although supporting evidence 
suggests a potential role of TNF-α as a modulator of obesity-induced insulin 
resistance, TNF-α’s mechanism of action leading to pathogenesis of insulin 
resistance and T2DM in humans remains to be determined [18]. 
TNF-α attenuates insulin signaling directly  
TNF-α attenuates insulin signaling through various proposed mechanisms, 
ultimately leading to insulin resistance.  TNF-α has a direct effect on insulin 
signaling by inhibiting insulin-stimulated tyrosine phosphorylation of the insulin 
receptor and insulin receptor substrate-1 (IRS-1), in part by induction of serine 
phosphorylation of IRS-1 through inhibitor of κβ kinase-β (IKK-β) [28].  Reduced 
insulin signaling over time impairs insulin signaling and leads to insulin 
resistance.  
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TNF-α indirectly promotes insulin resistance by enhancing lipolysis  
TNF-α leads to insulin resistance indirectly by enhancing lipolysis through 
activation of numerous signaling pathways.  First, TNF-α reduces the expression 
of various adipogenic genes at multiple levels, including the transcription, 
translation, and turnover of mRNA and protein (Figure 2). TNF-α activates 
nuclear factor-κB (NF-κB) to reduce the expression of peroxisome proliferator-
activated receptor γ (PPARγ), the master regulator of adipogenesis required for 
maintenance of mature adipocyte function (Figure 2) [29-31]. TNF-α promotes 
PPARγ mRNA turnover and degradation through NF-κB activation and PPARγ 
protein degradation by activation of caspases (Figure 2) [1]. TNF-α upregulates 
mitogen-activated protein kinase kinase kinase kinase-4 (MAP4K4) to inhibit 
PPARγ translation (Figure 2). Taken together, TNF-α activates various players at 
multiple levels of expression to decrease PPARγ activity [1]. In addition, a 
previous study has also demonstrated that TNF-α induced NF- κβ activation 
inhibits expression of many adipocyte-associated genes responsible for uptake 
and storage of FFA in 3T3-L1 adipocytes [18].  Downregulation of PPARγ 
expression along with other adipocyte-associated genes impairs adipogenesis 
and alters adipose tissue function as TG storage, hydrolysis, and deposition in 
the lipid droplet, enhancing the release of plasma FFA in circulation that impairs 
insulin signaling and leads to insulin resistance.  
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Figure 2: TNF-α attenuates adipogenesis by downregulating PPARγ [1]. (1) 
Peroxisome proliferator-activated receptor-γ (PPARγ) expression is 
downregulated at the transcriptional level by TNF-α through NF-κβ activation. (2) 
TNF-α enhances PPARγ mRNA turnover and degradation. (3) TNF-α 
upregulates mitogen-activated protein kinase kinase kinase kinase-4 (MAP4K4) 
to inhibit PPARγ translation. (4) TNF-α activates caspases to promote 
degradation of PPARγ protein. 
  
Another mechanism by TNF-α leads to insulin resistance is through 
chronic stimulation of lipolysis [1]. TNF-α suppresses perilipin (PLIN1) function by 
enhancing cAMP levels (Figure 3). Lack of PLIN1 increases the association of 
hormone sensitive lipase (HSL) with TG in the lipid droplet to increase basal 
lipolytic rate and circulating FFA (Figure 3) [1].   
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FSP27 regulates fat metabolism by protecting the lipid droplet from 
lipolysis and restore insulin sensitivity 
Synthesis, deposition, storage, and hydrolysis of adipocyte 
triglyceride require PPARγ-mediated regulation of adipocyte-regulatory proteins 
[31-33]. PPARγ regulates lipid droplet associated proteins like PLIN, S3-12, and 
myocardial lipid-droplet protein, which all serve important roles in association 
with the lipid droplets [34-36]. A novel lipid droplet associated protein, fat specific 
Figure 3: TNF-α increases basal lipolysis in adipocyte leading to insulin 
resistance [1]. High levels of TNF-α in obese adipocyte result in enhanced 
lipolysis and reduced FA esterification into TG. TNF-α attenuates PPARγ, 
GLUT4, LPL protein levels resulting in decreased glucose transport and fatty acid 
esterification. TNF-α stimulates lipolysis by increasing cAMP levels, activating 
HSL, and downregulating perilipin through activation of mitogen-activated protein 
kinase pathway. 
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protein 27 (FSP27, also known as CIDEC), has been found to protect the 
deposition and storage of TG in lipid droplets in adipocytes [37]. Experimental 
evidence solidifies the role of FSP27 in regulating the formation and destruction 
of lipid droplets in mice and humans.  Homozygous nonsense mutations in 
FSP27 are associated with lipodystrophy in white adipose tissue and depletion or 
mutation of FSP27 decreases lipid droplet size associated with hyperlipidemia in 
adipocytes [38, 39]. FSP27 protects adipocytes from lipolysis by regulating the 
lipolytic capacity as well as the transcription of ATGL [40]. 
FSP27 is co-localized with lipid droplets in adipocytes and is critical in 
enhancing lipid-droplet size in non-adipose cells as well [37, 41, 42]. In 
accordance with other lipid droplet associated proteins, FSP27 is under the 
influence of PPARγ, where its expression in mouse adipocytes increases 50-fold 
during adipogenesis [37].  
FSP27 has been proposed to play a potential role in protection against 
insulin resistance and the development of T2DM. FSP27, along with other lipid 
droplet associated proteins, promotes formation and deposition of TG into lipid 
droplets and decreases the release of plasma FFA through inhibition of lipolysis 
[1, 37, 43]. Decrease in circulating FFA in plasma attenuates the deleterious 
effect of excess FFA to maintain a normal insulin signaling and sensitivity in 
insulin-responsive tissues.  
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FSP27 protects against TNF-a mediated lipolysis in murine adipocytes 
Our lab has performed extensive research to confirm the regulatory role of 
FSP27 in lipid droplet morphology and adipocyte metabolism. We have shown 
that FSP27 is highly expressed in mouse adipocyte and is associated with lipid 
droplets [43]. Depletion of FSP27, mediated by short interfering RNA 
(siRNA), increases lipolysis of TG storage in adipocytes [44]. Overexpression of 
FSP27, on the other hand, enhanced TG deposition and accumulation in 
adipocytes [44]. To investigate the protective role of FSP27 in adipocyte 
metabolism during obesity-induced inflammation, our lab investigated the role of 
FSP27 in regulating TNF-α and catecholamine induced lipolysis in murine 
adipocytes. TNF-α treatment of mouse adipocytes increased lipolysis and 
depleted FSP27 levels and lipid droplet size. On the contrary, FSP27 
overexpression protected against TNF-α induced lipolysis and reduction of lipid 
droplet in mouse adipocytes. Taken together, FSP27 serves an essential role in 
protecting lipid droplet as a key target of TNF-α induced lipolysis in mouse 
adipocytes. In human adipocytes, however, the role of TNF-α in lipolysis and 
insulin resistance remains elusive. The aim of the present study is to identify the 
potential role of FSP27 in regulating lipolysis and insulin resistance in human 
adipocytes. We hypothesize that FSP27 protects against TNF-α induced lipolysis 
and FFA-induced impaired insulin signaling to restore impaired insulin sensitivity 
and insulin resistance in human adipocytes.  
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METHODS 
 Stromal vascular cells (adipose stem cells) handling 
   Isolated stromal vascular cells (adipose stem cells) from human adipose 
tissue were received from the Boston Nutrition Obesity Research Center 
adipocyte core. The cells were subcultured up to five passages, grown to 70-80% 
confluency, and frozen down in 10% dimethyl sulfoxide supplemented growth 
medium upon receiving. Frozen cells (5000 cells/ml/well) were seeded in a 12-
well plate in growth medium at 37°C composed of 13.5 g of alpha minimum 
essential medium power (Gibco), 10% fetal bovine serum (Gibco), 100 units/ml of 
penicillin and streptomycin (Gibco) and 25 mM sodium bicarbonate (Fisher 
Scientific) reconstituted in double distilled water (ddH2O) to 1 liter, pH 7.2-7.3.  
Cell culture   
Two days after the cells reached confluency, the medium was switched to 
adipogenic differentiation medium for induction [13.5 g of Dulbecco’s Modified 
Eagle’s medium (DMEM/F12) (Gibco) with 17.5 mM glucose, 100 units/ml of 
penicillin and streptomycin (Gibco) with 15 mM HEPES (Sigma), 25 mM sodium 
bicarbonate (Fischer Scientific), with 500 μM IBMX (Sigma), 100 nM insulin 
(Humulin), 100 nM Dexamethasone (Sigma), 1 μM Rosiglitazone (BioMol), 2 nM 
triiodothyronine (Sigma), 10 μg/mL transferrin (Sigma), 33 μM d-biotin (Sigma), 
and 17 μM pantothenic acid (Sigma) reconstituted in ddH2O to 1 liter, pH 7.4 ] 
[45]. D0 was indicated as the first day of the induction of differentiation. After 
induction in the differential media for 7 days, cells were kept in maintenance 
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medium (13.5 g of DMEM/F12 (Gibco), 25 mM sodium bicarbonate (Fischer 
Scientific), 100 units/ml of penicillin and streptomycin (Gibco), 33 μM d-biotin 
(Sigma), 17 μM pantothenic acid (Sigma) with 10 μM insulin and 10 nM 
dexamethasone in ddH2O to 1L in pH 7.4). Combination of insulin and 
dexamethasone in the medium has been shown to maintain adipocyte gene 
signatures [45]. Despite our labs incessant efforts to differentiate preadipocytes 
into mature adipocytes as much as possible, the degree of differentiation varied 
among the samples, with the majority of the cultures differentiated 40% to 60%. 
Generation of adenovirus and overexpression of FSP27 in adipocytes with 
viral infection 
The adenoviral constructs containing FSP27 with CFP and HA tags were 
generated as indicated by previous studies [40]. For infection of adipocytes, 75 
μL of FSP27 adenovirus was added directly to 500 μL of the well containing 
maintenance media for 48 hours on day 9 of differentiation. After 3 hours of 
administration of the virus, fresh maintenance medium was added and cells were 
incubated at 37°C for the remaining 45 hours. All experiments were designed 
such that the cells were exposed to virus 48 hours prior to the treatment with 
TNF-α.  
Lipolysis  
Glycerol release served as an indicator of lipolysis in culture media during 
TNF-α treatments. The cells were incubated in maintenance medium with 10 
ng/mL of TNF-α for 14 hours at 37°C. For the assessment of lipolysis, the 
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medium was changed from the maintenance medium to 500μL of Krebs- Ringer 
biocarbonate buffer [24.6 mM NaHCO3, 1.11mM KH2PO4, 130 mM NaCl, 4.7 mM 
KCl, 1.24 mM MgSO4, 3.3 mM CaCl2, 4% w/v bovine serum albumin (BSA), 5 
mM glucose in pH 7.4] still containing the indicated concentration of TNF-α 2 
hours prior to harvesting the cells. The buffer was then collected and analyzed 
for glycerol release under basal conditions. 12.5 μL KRB or consecutive dilutions 
of glycerol standard solution were combined with 50 μL of free glycerol reagent 
(Sigma) and incubated at 37°C for 15 minutes. Spectrophotometer (Bio-Rad) was 
used to quantify the absorbance at the wavelength of 540 nm.  Using the glycerol 
standards prepared, a standard curve was generated to extract values for 
concentrations of glycerol in each sample.  
Western Blotting 
After collecting KRB from cell culture, we washed the cells three times 
with ice-cold PBS. Then the cells were scraped off in 100 μL of cell lysis buffer 
with 5% sodium dodecyl sulfate, protease inhibitor cocktail (Roche) and 
phosphatase inhibitor cocktail (Roche). Cell lysates were sonicated to rupture the 
cell and centrifuged at 14,000 g for 10 min to obtain clear lysates. Clear layer 
with protein was transferred and 10 μg of protein was resolved in 12% bis-
acrylamide gels (BioRad) and transferred to polyvinylidene difluoride 
membranes. After blocking, blots were probed for endogenous FSP27 and 
FSP27-CFP (different molecular weights), phospho-AKT, and loading controls (β 
actin and total AKT). Primary antibodies used were diluted in 2% BSA in 200 mM 
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Tris(hydroxymethyl)aminomethane, 1.5 M NaCl, and 1% Tween20 with pH 7.5. 
Antibodies used were mouse anti-phopho-AKT in 1:1000 dilution (Invitrogen), 
and mouse anti-β-actin in 1:3000 dilution (Invitrogen). Secondary antibodies were 
purchased from Santa Cruz Biotechnology, administered in 1:5000 dilution. 
Chemiluminescence images were developed using Pierce CL‑Xposure Film 
(Thermo Scientific) and band intensities were quantified using Adobe Photoshop 
and ImageJ.  
Insulin Signaling 
 After the overnight treatment with 10 ng/mL of TNF-α, media was collected 
and the cells were washed with phosphate buffered saline (PBS) three times. 
Then Krebs Ringer HEPES (KRH) buffer with glucose was added without 
cytokine as a control, 10 ng/mL TNF-α for serum starvation. After 2.5 hours at 
37°C, the KRH was aspirated off and the cells were washed with PBS three 
times. After, KRH without glucose containing no cytokine as a control, TNF-α with 
or without insulin (10 nM) was added. Cells were incubated for 15 minutes at 
37°C. After 15 minutes, cells were washed twice with ice-cold PBS and 
harvested for analyzing AKT phosphorylation as a measure for insulin signaling. 
Phosphorylated AKT was normalized to total AKT.  
 In order to evaluate the protective effect of FSP27 on TNF-α mediated 
insulin resistance, the appropriate wells were treated with FSP27-CFP 
adenovirus on day 9 of differentiation. Cells were assessed for CFP expression, 
48 hours post infection. At 48 hours, differentiated adipocytes were incubated 
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with maintenance media as a control, 10 ng/mL for 16 hours at 37°C, and AKT 
phosphorylation was measured as described above.  
Statistics 
Results are expressed as means +/- SE, and the significance of the 
treatments was assessed using paired t-test (P<0.05) 
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RESULTS 
TNF-α increases lipolysis in differentiated human adipocytes  
TNF-α is an inflammatory cytokine that stimulates lipolysis in adipocytes 
[18]. To explore the impact of TNF-α on the rate of lipolysis on fully differentiated 
human adipocytes in culture, we first determined the optimal rate of TNF-α 
stimulated lipolysis by treating varying concentrations of TNF-α following different 
time periods and measured the rates of glycerol release. Based on the 
experimental designs from our lab's previous studies, TNF-α was added to 
human adipocytes in increasing dosages of 10, 20, and 50 ng/mL over 4, 8, and 
16 hours [44]. 10 ng/mL over 16 hours was the smallest concentration and 
shortest duration of TNF-α treatment that led to the strongest effect on lipolysis in 
human adipocytes (Figure 4). Although the effects of both 20 and 50 ng/mL of 
TNF-α treatments also induced lipolysis, the lower levels of glycerol release 
compared with 10 ng/mL TNF-α may be due to a toxic effect on human 
adipocytes (Figure 4).  These data are consistent with results from other studies, 
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confirming that TNF-α treatment increases lipolysis in differentiated human 
adipocytes [44, 46].  
Figure 4: TNF-α time course and dose dependent experiment reveals that 
10ng/mL over 16 hours gives the greatest increase in lipolysis rate in 
human adipocytes. 
 
TNF-α decreases FSP27 levels in differentiated human adipocytes  
Previous studies from our lab showed that TNF-α stimulates lipolysis and 
downregulates FSP27 levels and depletion of FSP27 leads to a greater rate of 
lipolysis in murine adipocytes [44]. To explore the impact of TNF-α on the 
expression of endogenous FSP27 in adipocytes, we determined the protein 
expression levels of FSP27 after 16 hour treatment with 10 ng/mL TNF-α on 
differentiated human adipocytes in culture. TNF-α treatment decreased the 
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expression of endogenous FSP27 protein levels compared to the control by more 
than 50% (Figure 5a, 5c). Overexpression of FSP27 rescued endogenous FSP27 
protein levels from TNF-α induced repression, but only partially to 50% of that of 
the control level (Figure 5a, 5c).  β-actin served as a loading control, where equal 
loading was evident as expected (Figure 5b). These data confirm that TNF-α 
decreases the expression of endogenous FSP27 and overexpression of FSP27 
is able to restore TNF-α induced repression of endogenous FSP27 to a certain 
degree. 
 
Figure 5: TNF-α decreases endogenous FSP27 protein expression when 
overexpression of FSP27 attenuates the inhibitory effect of TNF-α on 
endogenous FSP27 protein expression. (a) TNF-α administration decreases 
endogenous FSP27 protein expression; overexpression of FSP27 in TNF-α 
treatment increases endogenous FSP27 protein expression compared to that of 
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                              +FSP27    
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TNF-α alone, but is not effective in rescuing the endogenous FSP27 expression 
completely to that of the control. (b) β-actin expression levels are equal in all of 
the wells which serves as the loading control. (c) The intensities of the bands 
were collected and normalized; experiment done once in triplicate.  
 
Expression of adenoviral FSP27 protects against TNF-α mediated lipolysis 
 A previous study by our lab confirmed the protective effect of FSP27 
against TNF-α modulated lipolysis in murine adipocytes [44]. In order to test 
whether FSP27 regulates TNF-α induced lipolysis in differentiated human 
adipocytes, we first maintained the level of FSP27 in the presence of TNF-α by 
generating CFP-tagged FSP27 construct into an adenovirus expression system 
in differentiated human adipocytes in culture (Figure 6a) [40]. The rate of lipolysis 
increased to 20% following the treatment with TNF-α overnight (Figure 6b, 6c). 
Overexpression of FSP27-CFP reduced the rate of lipolysis by 70% compared to 
the basal level (Figure 6b, 6c). Overexpression of FSP27-CFP followed by TNF-α 
treatment overnight reduced the rate of lipolysis to slightly lower than the control 
level by 10% (Figure 6b, 6c). Overexpression of FSP27 not only reduced the rate 
of basal lipolysis, but also was able to reduce TNF-α induced lipolysis to the 
basal level (Figure 6b, 6c).  
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Figure 6: Overexpression of FSP27 protects against TNF-α induced 
lipolysis in human adipocytes. (a) Fluorescence of overexpression of FSP27-
CFP in human adipocytes. (b)-(c): Treatment of TNF-α alone increases the rate 
of lipolysis; Overexpression of FSP27 reduced the basal lipolysis rate; 
overexpression of FSP27 attenuates TNF-α induced lipolysis to that of the control 
or lower; experiment done in triplicate; *Statistically significant compared to 
control p<0.05; **statistically significant compared to each other p<0.05. 
 
TNF-α inhibits insulin signaling by interfering with activation of AKT in 
human adipocytes 
 TNF-α inhibits insulin signaling through various pathways. Studies have 
confirmed its role in rodent models where insulin signaling is reduced with TNF-α 
treatment in adipocytes [22, 24, 25, 28, 47, 48]. To test whether TNF-α inhibits 
insulin signaling in human adipocytes, we maintained the level of FSP27 in the 
presence of TNF-α with FSP27-CFP overexpression in differentiated human 
adipocytes in culture. We treated the cells with 10 ng/mL of TNF-α overnight, 
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then starved the cells, and subsequently stimulated the cells with glucose and 10 
nM insulin. TNF-α treatment decreased insulin stimulated AKT phosphorylation 
compared to that of the insulin stimulated treatment down to about 75% (Figure 
7a, 7c). Although the loading control shows TNF-α treated proteins are loaded 
more than others, there is still a remarkable reduction in phosphorylated AKT 
levels when normalized (Figure 7b, 7c).  Taken together, these data suggest that 
TNF-α reduces phosphorylation of AKT and thus inhibits its activation in insulin 
signaling pathway in human adipocytes.  
Expression of adenoviral FSP27 protects against TNF-α induced insulin 
resistance by activating AKT in human adipocytes 
Given our lab’s finding that FSP27 protects against TNF-α induced 
lipolysis in murine adipocytes and FFA induced impairment of insulin signaling in 
human adipocytes, we examined whether FSP27 expression attenuates TNF-α 
induced impairment of insulin signaling in human adipocytes [40, 44]. Following 
the expression of FSP27-CFP, we treated the cells with 10 ng/mL TNF-α 
overnight. Then we starved and subsequently stimulated the cells with glucose 
and 10 nM insulin. FSP27-CFP overexpression partially rescued phosphorylation 
of AKT from inhibitory effect of TNF-α (Figure 7a, 7c). FSP27 overexpression 
with TNF-α treatment appeared to activate AKT more than the insulin-stimulated 
control (Figure 7a). This may be attributed to the unequal loading of the protein, 
but the effect of FSP27 in attenuating TNF-α induced inhibition of AKT 
phosphorylation and restoring AKT activation is clearly demonstrated even after 
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normalization with total AKT (Figure 7c). FSP27 overexpression restored AKT 
phosphorylation to more than 60% of insulin stimulated levels of AKT 
phosphorylation (Figure 7c).  In conclusion, these data suggest that FSP27 
protects against TNF-α induced inhibition of insulin signaling in human 
adipocytes. More studies are needed to confirm the protective effect of FSP27 
against TNF-α induced insulin resistance.  
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Figure 7: TNF-α decreases phosphorylation of AKT but overexpression 
of FSP27 attenuates the inhibitory effect of TNF-α on AKT 
phosphorylation and rescues AKT activation. (a) TNF-α administration 
decreases p-AKT protein levels; overexpression of FSP27 in TNF-α treatment 
rescues the inhibitory effect of TNF-α and restores the AKT activation to more 
than the insulin-stimulated control level. (b) Total AKT expression levels are 
unequal in the controls and the treatments but shows protective effect of 
FSP27 on rescuing the phosphorylation of AKT in presence of TNF-α. (c) The 
intensities of the bands were collected and normalized; experiment done once 
in triplicate 
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DISCUSSION 
 In obesity, adipocytes become hypertrophied from nutrient excess and 
experience hypoxic environment from increased cell size [1]. Hypertrophy and 
hypoxia leads to local inflammation in the adipose tissue to stimulate release of 
pro-inflammatory cytokines, such as TNF-α, to further induce chronic 
inflammation and enhanced lipolysis in adipocytes [20]. Although the mechanism 
remains unclear, TNF-α has been proposed to be the major player linking obesity 
to insulin resistance and T2DM through inhibition of insulin signaling and 
reduction of insulin sensitivity [18]. TNF-α most commonly acts through indirect 
mechanisms by activating various signaling pathways to enhance lipolysis in 
adipocytes [18]. Both Zhang et al. and Lee and Fried propose a mechanism in 
which TNF-α promotes insulin resistance by stimulating lipolysis through 
activation of PKA signaling pathway in human adipocytes [5, 49]. Other studies 
also propose a possible mechanism through which TNF-α reduces overall insulin 
sensitivity by stimulating lipolysis by downregulating PLIN expression at the 
mRNA and protein levels in 3T3-L1 adipocytes through PKA signaling pathway 
[50]. Thus, in the present study, we examined whether the regulation and 
protection of lipolysis could restore insulin signaling and sensitivity from TNF-α 
induced lipolysis and insulin resistance in human adipocytes. We utilized FSP27 
to control lipolysis considering its role in protecting the lipid droplet from lipolysis 
in mice and human adipocytes in addition to its role in regulating ATGL’s lipolytic 
capacity as well as its transcription [40]. Also, FSP27 has been shown to interact 
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directly with other lipid droplet-associated proteins and to regulate their mRNA 
levels to encourage TG synthesis and deposition and attenuate lipolysis [40].  
In agreement with Lee and Fried, our data confirm that TNF-α stimulates 
lipolysis in differentiated human adipocytes [5]. Moreover, the present study 
showed that TNF-α causes a dramatic depletion of endogenous FSP27 in 
cultured human adipocytes. We also demonstrated that restoration of FSP27 
protein levels by adenovirus-mediated overexpression attenuates TNF-α induced 
lipolysis. These results suggest that depletion of FSP27 is a possible mechanism 
acting in parallel with other mechanisms by which TNF-α triggers lipolysis in 
human adipocytes. Downregulation of transcription of FSP27 by TNF-α could 
also be attributed to the decrease in C/EBPα levels and decrease in PPARγ 
protein levels which all take part in regulating FSP27 activity and producing 
FSP27 proteins in adipocytes [29, 31, 42, 51].  Ranjit et al. has shown that TNF-α 
treatment downregulates FSP27 at a transcriptional level in 3T3-L1 adipocytes, 
but further studies are encouraged to examine the effect of TNF-α at translational 
level to see how TNF-α affect the protein itself in both animal and human 
adipocytes to enhance lipolysis [44]. 
We confirmed that FSP27 serves as a modulator to control lipolysis in 
TNF-α induced lipolysis in cultured human adipocytes. FSP27 regulation of 
lipolysis is not confined to actions of TNF-α specifically, but rather extends to a 
variety of proinflammatory cytokines such as with IL-1β and IL-6 to inhibit their 
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actions from triggering lipolysis in human adipocytes by reducing FSP27 protein 
levels (unpublished).   
Prolonged exposure to high FFA from enhanced lipolysis may desensitize 
insulin signaling in adipocytes and develop into insulin resistance.  To define the 
role of FSP27 in insulin signaling in human adipocytes, we showed that inhibition 
of insulin-stimulated AKT phosphorylation by TNF-α was countered by FSP27 
overexpression in cultured human adipocytes. TNF-α treatments reduced the 
insulin-stimulated AKT activation and insulin signaling. However, overexpression 
of FSP27 restored inhibition of insulin-stimulated AKT activation by TNF-α in 
human adipocytes [40]. FSP27 overexpression protected against FFA-induced 
insulin resistance in human adipocytes. These results suggest that FSP27 may 
protect from FFA-induced insulin resistance through suppression of lipolysis in 
human adipocytes. 
Although we only examined the indirect effect of TNF-α in promoting 
insulin resistance through mechanism enhancing lipolysis, TNF-α has been 
proposed to act directly to block insulin signaling through inhibition of tyrosine 
phosphorylation of the IRS-1 partly by induction of serine phosphorylation of IRS-
1 by the actions of IKK-β [28, 52]. FSP27 may interact directly with insulin 
signaling pathways to inhibit the actions of TNF-α. Further studies need to be 
performed to find additional roles of FSP27 in protecting against TNF-α induced 
insulin resistance and development of T2DM.  
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Optimal fat storage in adipocytes is essential to maintain a healthy 
metabolic phenotype and whole body glucose homeostasis [1, 53-56]. In obese 
individuals, where production of proinflammatory cytokines, such as TNF-α, are 
at maxima, increased lipolysis in adipocytes produce uncontrolled, excessive 
FFA release into circulation. Prolonged exposure to high FFA in circulation may 
desensitize insulin signaling and develop into insulin resistance and T2DM.  The 
present study suggests that FSP27 may protect from TNF-α induced insulin 
resistance through suppression of lipolysis in human adipocytes. Potential role of 
FSP27 in regulating TG accumulation and reducing lipolysis in human 
adipocytes opens up new windows for therapeutic remedies to combat obesity-
related insulin resistance and development of T2DM.
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